496 related articles for article (PubMed ID: 16231851)
1. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
3. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
[TBL] [Abstract][Full Text] [Related]
4. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia.
Kay NE; Geyer SM; Call TG; Shanafelt TD; Zent CS; Jelinek DF; Tschumper R; Bone ND; Dewald GW; Lin TS; Heerema NA; Smith L; Grever MR; Byrd JC
Blood; 2007 Jan; 109(2):405-11. PubMed ID: 17008537
[TBL] [Abstract][Full Text] [Related]
5. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
Lamanna N; Kalaycio M; Maslak P; Jurcic JG; Heaney M; Brentjens R; Zelenetz AD; Horgan D; Gencarelli A; Panageas KS; Scheinberg DA; Weiss MA
J Clin Oncol; 2006 Apr; 24(10):1575-81. PubMed ID: 16520464
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia.
Ioakimidis L; Patterson CJ; Hunter ZR; Soumerai JD; Manning RJ; Turnbull B; Sheehy P; Treon SP
Clin Lymphoma Myeloma; 2009 Mar; 9(1):62-6. PubMed ID: 19362976
[TBL] [Abstract][Full Text] [Related]
8. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia.
Treon SP; Hunter Z; Barnagan AR
Clin Lymphoma; 2005 Mar; 5(4):273-7. PubMed ID: 15794864
[TBL] [Abstract][Full Text] [Related]
9. A phase I and II study of pentostatin (Nipent) with cyclophosphamide for previously treated patients with chronic lymphocytic leukemia.
Weiss MA
Semin Oncol; 2000 Apr; 27(2 Suppl 5):41-3. PubMed ID: 10877051
[TBL] [Abstract][Full Text] [Related]
10. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
11. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
12. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of rituximab-containing regimens on indolent B-cell lymphoma--a report of 34 cases].
Xia ZJ; Wang FH; Huang HQ; Luo HY; Li YH; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):490-4. PubMed ID: 16613687
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
[TBL] [Abstract][Full Text] [Related]
15. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.
Weiss MA; Maslak PG; Jurcic JG; Scheinberg DA; Aliff TB; Lamanna N; Frankel SR; Kossman SE; Horgan D
J Clin Oncol; 2003 Apr; 21(7):1278-84. PubMed ID: 12663715
[TBL] [Abstract][Full Text] [Related]
16. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
17. [Complete response achieved after rituximab plus CHOP therapy in a patient with rapidly progressing Waldenstrom's macroglobulinemia].
Ise M; Sakai C; Kumagai K
Rinsho Ketsueki; 2009 Jan; 50(1):34-8. PubMed ID: 19225227
[TBL] [Abstract][Full Text] [Related]
18. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
19. Accelerated R-COP: a pilot study for the treatment of advanced low grade lymphomas that has a high complete response rate.
Levitt MJ; Gharibo M; Strair R; Schaar D; Rubin A; Bertino JR
J Chemother; 2009 Aug; 21(4):434-8. PubMed ID: 19622463
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
